COO
The Cooper Companies, Inc.
COO's fundamentals are mixed, but it looks cheap: trading at 21x earnings, about half its usual 41x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
COO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
COO's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
COO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $62.19 | — |
| Cheap | 17x | $50.37 | -19% |
| Current | 21x | $62.19 | — |
| Fair | 40x | $117 | +89% |
| Expensive | 61x | $179 | +189% |
Historical ranges are pointers, not guarantees.
COO's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
COO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect COO's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
COO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.64 | +59% |
| Q3 2026 | $2.92 | +43% |
| Q2 2026 | $1.17 | -43% |
| Q1 2026 | $2.01 | -2.9% |
| Q4 2025 | $1.87 | -4.6% |
| Q3 2025 | $2.04 | +14% |
| Q2 2025 | $2.07 | +22% |
| Q1 2025 | $2.07 | +42% |
| Q4 2024 | $1.96 | +32% |
COO has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
COO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +0.6% |
| Q2 2026 | $1.1B | +7.9% |
| Q1 2026 | $1B | +6.2% |
| Q4 2025 | $1.1B | +4.6% |
| Q3 2025 | $1.1B | +5.7% |
| Q2 2025 | $1B | +6.3% |
| Q1 2025 | $964.7M | +3.6% |
| Q4 2024 | $1B | +9.8% |
COO's revenue has grown year over year for 23 quarters in a row: $1.1B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +4.3 points |
| Q2 2026 | -2.9% | -21 points |
| Q1 2026 | 21% | +1.9 points |
| Q4 2025 | 13% | -6.3 points |
| Q3 2025 | 17% | -2.6 points |
| Q2 2025 | 18% | +1.3 points |
| Q1 2025 | 19% | +2.4 points |
| Q4 2024 | 19% | +4.8 points |
COO has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over COO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
COO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $273M | +66% |
| Q2 2026 | $96.4M | +433% |
| Q1 2026 | $158.7M | +57% |
| Q4 2025 | $149.9M | +17% |
| Q3 2025 | $164.5M | +39% |
| Q2 2025 | $18.1M | -51% |
| Q1 2025 | $101.2M | +2100% |
| Q4 2024 | $128.1M | +339% |
COO generated $678M in free cash flow over the past year, up 65% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
COO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -1.6M shares |
| 1 year | -3.3% | -6.6M shares |
| 3 years | -3.1% | -6.2M shares |
| 5 years | -2.9% | -5.8M shares |
| Available history | -3.3% | -6.6M shares |
COO has 193M diluted shares, down 3.3% from a year ago, with $644M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $339.2M |
| Q2 2026 | $15.5M |
| Q1 2026 | $92.5M |
| Q4 2025 | $196.8M |
| Q3 2025 | $52.7M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
COO spent $644M buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over COO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
COO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.2x | Moderate |
| Q4 2024 | 2.3x | Moderate |
COO's net debt is about 2.6 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
COO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.3 | Neutral |
| Stochastic | 38.2 | Neutral |
COO's weekly RSI is 46 (neutral) and its Stochastic is 38 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
COO PE vs Healthcare Sector
| Metric | COO | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 18% below |
| PE % | 22 | 29 | 7 pts below |
COO is trading at 21x earnings, a 18% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
COO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $58.7 | 5.9% above |
| 20 week MA | $65.3 | 4.7% below |
| 50 week MA | $70.3 | 12% below |
| 100 week MA | $74.3 | 16% below |
| 200 week MA | $83.9 | 26% below |
COO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
COO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.3 | $89.6 | +12% |
| 2021 | $89.6 | $102.8 | +15% |
| 2022 | $102.8 | $83.2 | -19% |
| 2023 | $83.2 | $94.6 | +14% |
| 2024 | $94.6 | $92.3 | -2.4% |
| 2025 | $92.3 | $82.6 | -11% |
| 2026 YTD | $82.6 | $62.2 | -25% |
COO has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.